Skip to main content
Frontier Biotechnologies Inc. logo

Frontier Biotechnologies Inc. — Investor Relations & Filings

Ticker · 688221 ISIN · CNE100005XF5 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 570 across all filing types
Latest filing 2022-04-29 Management Reports
Country CN China
Listing Shanghai Stock Exchange 688221

About Frontier Biotechnologies Inc.

https://www.frontierbiotech.com/

Frontier Biotechnologies Inc. is a biopharmaceutical company focused on the research, development, and commercialization of innovative medicines, particularly in the field of anti-infectives. The company's flagship product is albuvirtide, a long-acting HIV fusion inhibitor administered via injection. This therapeutic represents a significant advancement in HIV management by providing a long-acting alternative to daily oral regimens. Frontier Biotechnologies maintains a diverse pipeline of clinical-stage candidates, including protease inhibitors developed for the treatment of COVID-19. The company leverages its proprietary technology platforms to develop long-acting peptide drugs and small molecule therapeutics targeting unmet medical needs in infectious diseases and chronic conditions. Its core operations encompass the full drug development lifecycle, from discovery and clinical trials to manufacturing and commercial distribution.

Recent filings

Filing Released Lang Actions
前沿生物2021年度独立董事述职报告
Management Reports Classification · 95% confidence The document is titled as the "2021年度独立董事述职报告" which translates to "2021 Annual Independent Directors' Work Report." It details the independent directors' activities, attendance at board and shareholder meetings, committee work, oversight on related party transactions, external guarantees, fundraising usage, mergers and acquisitions, senior management nominations and remuneration, performance forecasts, auditor appointment, dividend distribution, information disclosure, internal controls, and overall evaluation and suggestions. The content is a detailed report on the independent directors' duties and oversight for the year 2021. This type of document is a management report focusing on governance and oversight activities rather than a full annual report or audit report. It is not a brief announcement or a certification but a substantive report on management and governance activities. Therefore, the most appropriate classification is Management Reports (MDA). The document length is 3753 characters, which is sufficient for a detailed report but not a full annual report. No indication that this is an announcement or a proxy statement. Hence, classification as MDA is appropriate with high confidence.
2022-04-29 Chinese
毕马威华振会计师事务所（特殊普通合伙）关于前沿生物药业（南京）股份有限公司非经营性资金占用及其他关联资金往来情况汇总表的专项审计报告
Audit Report / Information Classification · 95% confidence The document is titled as a "专项审计报告" which translates to a "Special Audit Report" concerning non-operating fund occupation and other related party fund transactions for the year 2021. It is prepared by an audit firm (毕马威华振会计师事务所) and includes detailed tables of financial data related to these transactions. The content is focused on audit findings and financial details related to specific audit matters rather than a full annual report or general financial statements. The document length is 2250 characters, which is relatively short but contains substantive audit information and financial data. This fits the definition of an Audit Report / Information (AR) rather than a full Annual Report (10-K) or a simple announcement. Therefore, the appropriate classification is AR with high confidence. FY 2021
2022-04-29 Chinese
前沿生物关于第二届董事第二十二次会议决议的公告
Board/Management Information Classification · 95% confidence The document is a detailed announcement of resolutions passed at the 22nd meeting of the second board of directors of the company. It includes approvals of various reports such as the 2021 annual report, financial statements, internal control reports, and plans for capital raising through a simplified procedure for issuing A shares to specific investors. It also covers board elections and amendments to company bylaws. The document references multiple reports and announcements that are disclosed separately on the stock exchange website, indicating this document itself is a meeting resolution announcement rather than the reports themselves. The content focuses on board decisions and management approvals, including board member nominations and governance matters. Therefore, the document fits best under the category of Board/Management Information (MANG), as it primarily announces board meeting resolutions and management decisions.
2022-04-29 Chinese
前沿生物独立董事提名人声明-CHI KIT NG（吴智杰）
Board/Management Information Classification · 100% confidence The document is a formal statement nominating an independent director candidate for the company's board. It details the qualifications, independence criteria, and compliance with regulatory requirements for the nominee. There is no financial data, no report or results, no meeting minutes or voting results, and no mention of any report publication or regulatory filing. The content is focused on board/management information, specifically the nomination of a board member. Therefore, the document fits best under the category of Board/Management Information (MANG). The document length is short and does not indicate it is an announcement of a report or a certification, so it is not RNS or RPA.
2022-04-29 Chinese
前沿生物独立董事候选人声明-王广基
Board/Management Information Classification · 95% confidence The document is a statement by an independent director candidate declaring qualifications, independence, and compliance with regulatory requirements. It is not a financial report, earnings release, or any form of meeting material. It relates to board/management information specifically about a director candidate's declaration. The document length is short (1900 characters), and it is a formal declaration rather than a report or announcement of voting results. Therefore, it fits best under Board/Management Information (MANG).
2022-04-29 Chinese
前沿生物独立董事候选人声明-KAI CHEN（陈凯）
Board/Management Information Classification · 95% confidence The document is a statement by an independent director candidate, KAI CHEN, declaring qualifications, independence, and compliance with relevant laws and regulations for serving as an independent director of the company. It includes detailed legal and regulatory references and personal commitments but does not contain financial data, audit results, or report content. It is not an annual report, audit report, or any financial report. It is also not a voting result or a proxy solicitation. The document is a formal declaration related to board/management information, specifically about a board candidate's qualifications and independence. Therefore, it fits best under Board/Management Information (MANG). The document length is short and focused on management nomination and qualifications, confirming this classification with high confidence.
2022-04-29 Chinese

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.